Health ❯Pharmaceuticals

Weight Loss

GLP-1 Drugs Clinical Trials GLP-1 Medications GLP-1 Agonists Semaglutide Drug Development Novo Nordisk Obesity Treatment GLP-1 Treatments Obesity Treatments FDA Approvals GLP-1 Inhibitors GLP Inhibitors Addiction Treatment Compounded Drugs Diabetes Drug Safety Medications Incretin Drugs Weight Loss Pills Medication Childhood Obesity GLP-1 Analog Drugs Prescription Drugs Drug Pricing Obesity

Roche and Zealand Partner in $5.3 Billion Deal for Obesity Drug Development

Eli Lilly Targets Unapproved Weight-Loss Drugs with New Ad Campaign

Weight Loss Industry Transformed by New Drugs and Emerging Alternatives

Terry Smith Sells Diageo Stake Over Concerns About Weight-Loss Drugs' Impact

Weight Loss Drugs Reshape Food Industry and Consumer Habits

GLP-1 Drugs Show Promise Beyond Diabetes and Obesity but Raise Cost and Ethical Concerns

Elon Musk Promotes Weight-Loss Drug Mounjaro in Viral 'Ozempic Santa' Post

Elon Musk and RFK Jr. Clash Over Weight-Loss Drug Policies

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism

Novo Nordisk Launches Wegovy in China at Lower Price Point

Scotland Faces Health Crisis Linked to Weight-Loss Injections

Novo Nordisk Expands Wegovy Supply Amid Compounding Drug Concerns

Cost and Efficacy Concerns Arise for GLP-1 Weight Loss Drugs

Wegovy and Ozempic: Celebrity Trends and Health Risks

New Research Highlights Key Factors for Effective Weight Loss with GLP-1 Drugs

Novo Nordisk's Amycretin Pill Shows Promising Weight Loss Results in Early Trial

Compounded Weight Loss Drugs Raise Safety and Ethical Concerns

Viking Therapeutics Advances Weight-Loss Drug, Shaking Up Market Leaders

Roche's New Weight Loss Pill Shakes Up Pharmaceutical Market